Retrospective Analysis of Intravascular Large B-Cell Lymphoma Treated With Rituximab-Containing Chemotherapy As Reported by the IVL Study Group in Japan

Abstract

Our data suggest improved clinical outcomes for patients with IVLBCL in the rituximab era. Future prospective studies of rituximab-containing chemotherapies are warranted.

A unifying diagnosis for pancytopenia, fever, hypoglycemia, and lactic acidosis

“…Treatment outcomes have significantly improved with the addition of rituximab to standard anthracycline based chemotherapy. Shimada et al [12] compared treatment outcomes for IVLBCL in Asian patients using chemotherapy with and without rituximab and noted a significantly higher complete response rate (82% rituximab group versus 51% nonrituximab group) and progression-free/overall survival at 2 years (56%/66% rituximab group; 27%/46% nonrituximab group). Similar results were achieved in a report from Ferreri et al [19] using immunochemotherapy in Western patients.…”

“…IVLBCL is usually treated with anthracycline-containing regimen. Since the lymphoma cells are CD201, rituximab had to be a part of the treatment regimen [12]. Serology for infectious hepatitis had to be obtained prior to therapy with rituximab.…”

“…As mentioned earlier, rituximab had to be added to the regimen due to improved clinical outcomes in patients treated with rituximab [12]. Unfortunately, his liver dysfunction precludes use of standard-dose CHOP chemotherapy.…”

Treatment of Diffuse Large B-Cell Lymphoma

“…A retrospective study suggested a survival benefit with the addition of R to chemotherapy for IVLBCL; the 2-year OS for 49 patients treated with R-chemotherapy was significantly higher than that of 57 patients treated with chemotherapy alone (66% vs. 46%; p = 0.02). 48 In IVLBCL patients without CNS involvement at initial diagnosis, the risk of CNS recurrence at 3 years was 25% with a median follow-up in survivors of 39 mon. 49 At present, a phase II trial of R-CHOP combined with high-dose-methotrexate (HD-MTX) and intrathecal administration of MTX to prevent CNS relapse for untreated IVLBCL is ongoing in Japan (UMIN000005707).…”

Isolated renal intravascular lymphoma: a case report and review of the literature

“…Among the patients with IVLBCL, the 2-year survival and progression-free survival rates in the rituximab group were 66% and 56%, compared to the group without rituximab, 46% and 27% respectively. 22 IVLBCL is a very rare cause of nephrotic syndrome and acute kidney injury. FDG-PET-CT may be especially very helpful for the early diagnosis of IVLBCL.…”